オッセオインテグレーテッドプロテーゼ患者の感染を防ぐための抗菌光力学療法の進歩
This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.
All eligible consenting patients will undergo daily stoma management per standard of care.
Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.
Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.
Follow-up: Study participants will be followed at 1 week and 2 weeks.
調査の概要
状態
条件
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Devin Mullin
- 電話番号:603-650-6032
- メール:Devin.S.Mullin@hitchcock.org
研究連絡先のバックアップ
- 名前:Ida Gitajn
- 電話番号:603-650-6032
- メール:Ida.Leah.Gitajn@hitchcock.org
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20889
- Walter Reed National Military Medical Center
-
コンタクト:
- Christopher H Renninger, MD
- 電話番号:(202)-929-0618
- メール:christopher.h.renninger.mil@health.mil
-
コンタクト:
- Qingfeng Liu
- 電話番号:(240) 645-3068
- メール:Qingfeng.liu.ctr@usuhs.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
All patients >18 years with osseointegrated prostheses are eligible. Patients will be excluded if they have an ongoing infection, are pregnant or if it is anticipate that they will have issues with compliance or follow-up.
説明
Inclusion Criteria:
- All patients with osseointegrated prostheses 18 years of age or older
Exclusion Criteria:
- Ongoing infection
- Pregnant
- Anticipated issues with compliance or follow-up
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Osseointegration patients
All patients >18 years with osseointegrated prostheses. |
All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device as part of their standard stoma management. All patients who are recruited and enrolled into this study use topical 5- ALA, in combination with the light delivery device photodynamic therapy device as part of their standard stoma management. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility
時間枠:2 weeks
|
Feasibility will be defined as 80% of patients successfully completing the administration protocol as well as 1 week/2-week follow-up. |
2 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Treatment Evaluation Inventory-Short Form (TEI-SF)
時間枠:2 weeks
|
The TEI-sf is a 9-item questionnaire used to measure intervention acceptability from the participants point of view. Scores range from 9 to 45, and scores above 27 are considered acceptable. |
2 weeks
|
|
System Usability Scale (SUS)
時間枠:2 weeks
|
The SUS is a reliable 10-item usability measure with scores that range from 0 to 100 (an above average score is 68 or higher. |
2 weeks
|
|
Bioburden quantification (16S rRNA sequencing)
時間枠:2 weeks
|
Bioburden will be quantified using quantitative PCR-based assays as well as addition of a "spikein" of a defined quantity of bacterial cells derived from halophilic organism Salnibacter ruber. |
2 weeks
|
|
Bioburden quantification (Optical Coherence Tomography (OCT)
時間枠:2 weeks
|
Biofilm will be imaged and quantified on the metal abutment |
2 weeks
|
|
OCT "virtual biopsy"
時間枠:2 weeks
|
Presence of inflammation, hypergranulation, and any resulting changes (e.g., the degree of epidermal regression, dermal attachment to the implant, and epithelial layer thickness) can be quantified through morphologic analysis of the OCT B-scans. Scars are characterized by excessive collagen deposition, increased blood vessel density, and parallel blood vessel organization compared with normal skin. |
2 weeks
|
|
Scar thickness
時間枠:2 weeks
|
Scar thickness measured using OCT |
2 weeks
|
|
Blood vessel density
時間枠:2 weeks
|
Blood vessel density measuring using OCT |
2 weeks
|
|
Presence of hypergranulation
時間枠:2 weeks
|
Hypergranulation measured using OCT |
2 weeks
|
|
Pain during light exposure
時間枠:2 weeks
|
Patient reported pain during light exposure |
2 weeks
|
|
Discomfort, burning, itchiness, or redness
時間枠:2 weeks
|
Patient reported discomfort, burning, itchiness or redness |
2 weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。